跳至主要内容
临床试验/ISRCTN19893319
ISRCTN19893319已完成未知

Observational Epidemiological Study of disease progression and therapeutic approach in prostate Cancer Patients: an observational study

Astelas Pharma S.A. (Spain)0 个研究点目标入组 4,087 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
4,087

研究概览

简要总结

2016 results in https://pubmed.ncbi.nlm.nih.gov/26723895/ (added 25/06/2020) 2017 results in https://pubmed.ncbi.nlm.nih.gov/28285790/ (added 25/06/2020) 2019 results in https://pubmed.ncbi.nlm.nih.gov/29891440/ (added 25/06/2020)

研究设计

研究类型
Observational

入排标准

性别
Male

入选标准

  • Patient that was included in the study with code CaP01-10 with newly diagnosed, histopathologically confirmed PCa in any stage, between 1 January and 31 December 2010

排除标准

  • Patients who have withdrawn their informed consent to take part in the study

研究者

发起方
Astelas Pharma S.A. (Spain)

相似试验